Concepedia

Publication | Closed Access

Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas

DOI

73

Citations

44

References

2013

Year

Renata S. Auriemma, Rosario Pivonello, Ylenia Perone, Ludovica F. S. Grasso, Lucia Ferreri, Chiara Simeoli, Davide Iacuaniello, Maurizio Gasperi, Annamaria Colao
European Journal of Endocrinology

Abstract

CAB does not increase the risk of significant cardiac valve regurgitation in prolactinomas after the first 5 years of treatment.

References

YearCitations

Page 1